GO
Loading...

AstraZeneca PLC

More

  • War Against Superbugs Likely Unwinnable: Doctors Thursday, 4 Apr 2013 | 8:32 AM ET
    Virus

    In addition to superbugs' deadly human toll, associated health costs run into the billions. Some warn that we may never win our war against them as research tapers off.

  • Early Movers: CAG, TSLA, VZ & More Wednesday, 3 Apr 2013 | 8:14 AM ET

    Some of the names on the move ahead of the open.

  • European Shares Close Higher After 2-Week Slide Tuesday, 2 Apr 2013 | 12:26 PM ET

    European shares closed higher on Tuesday, led by the telecoms sector, which was boosted by new reports that Vodafone, the world's second largest mobile operator, could be bought.

  • Early Movers: Insurers, NDAQ, AAPL & More Tuesday, 2 Apr 2013 | 8:01 AM ET

    Some of the names on the move ahead of the open.

  • Early Movers: DG, APOL, SFD & More Monday, 25 Mar 2013 | 7:45 AM ET

    Some of the names on the move ahead of the open Monday:

  • Early Movers: LULU, ORCL, JBL & More Thursday, 21 Mar 2013 | 8:00 AM ET

    Some of the names on the move ahead of the open.

  • U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.

  • Denmark's Nokia Moment on $100 Billion Stock Friday, 1 Feb 2013 | 6:37 AM ET
    Copenhagen, Denmark

    Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.

  • Denmark Faces Nokia Moment on $100 Billion Stock Friday, 1 Feb 2013 | 5:28 AM ET

    Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.

  • Europe Shares Close Lower as Earnings Weigh Thursday, 31 Jan 2013 | 10:14 AM ET

    European shares pared some of the losses on Thursday, after a series of earnings across the continent weighed on market sentiment.

  • Best Move of the Year? Playing the Flu Tuesday, 29 Jan 2013 | 12:45 PM ET
    A man is given a flu shot by at the medical offices of Yaffe Ruden & Associates in New York.

    Amid all the bullishness about stocks this year, the swine flu play may be getting lost. Yes, one of the most effective strategies has been betting on shares of companies that benefit from the higher-than-expected flu cases.

  • Earnings Buzz: What to Watch in the Week Ahead Friday, 25 Jan 2013 | 4:41 PM ET

    Earnings season is shifting into high gear in the final week of January, with six Dow Jones components, and more than a fifth of the S&P 500 companies reporting.

  • Bye-Bye, Big Bonuses: Hello Claw-Backs and Caps Thursday, 3 Jan 2013 | 11:16 PM ET
    Big Banks Still Needed to Keep US Competitive: Bove

    Another nail in the coffin of pre-credit crisis bonus culture is set to come with the 2012-13 bonus season.

  • Europe Close Lower as Investors Lock in Profits Friday, 14 Dec 2012 | 11:36 AM ET

    European shares closed slightly lower on Friday as investors locked in profits ahead of the weekend and once again focused on the ongoing discussions surrounding the "fiscal cliff" in the U.S.

  • Early Movers: CLWR, S, BBY & More Thursday, 13 Dec 2012 | 7:54 AM ET

    Some of the names on the move ahead of the open.

  • Ever since James Watson and Francis Crick discovered the structure of DNA in 1953, scientists have been puzzling over how genes make us who we are.

  • AstraZeneca deepens collaboration with academia Wednesday, 31 Oct 2012 | 12:01 AM ET

    LONDON, Oct 31- British academic researchers have secured 7 million pounds of funding from the country's Medical Research Council to investigate a range of potential new drugs made available free-of-charge by AstraZeneca. AstraZeneca did initial tests on these chemicals but then put them on hold for a variety of reasons.

  • *AstraZeneca, Sanofi, Novartis all hit by patent loss in Q3. *Sanofi, Novartis forecast to post rises of 21 pct, 9 pct. While AstraZeneca faces years of continuing sales declines, due to a lack of new drugs to replace those losing protection, Sanofi and Novartis are turning the corner.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. *Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.